---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-328716"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2026-07-31T20:31:37+00:00"
generated_at: "2026-07-31T20:33:12.576620+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galera completes $350M PIPE financing; merger with Obsidian expected to close Aug 3, 2026

## Summary
- Closed $350M PIPE sale of Series C Preferred Stock to qualified investors on July 31, 2026.
- Merger with Obsidian expected to close August 3, 2026, subject to customary conditions.
- Pre-Closing Distribution of CVRs to common stockholders: record date July 31, distribution date Aug 6.
- Each CVR entitles holder to net proceeds from future disposition of tilarganine and GC4711/GC4419 assets.

## SEC filing metadata
- accession: 0001193125-26-328716
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2026-07-31T20:31:37+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312526328716/0001193125-26-328716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312526328716/d138144d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-328716
- JSON: https://secwatch.observer/filing/0001193125-26-328716.json
- Plain text: https://secwatch.observer/filing/0001193125-26-328716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.